United Therapeutics

United Therapeutics Corp earns a 1-star quantitative star rating, indicating our belief that this share class poses considerable downside risk. Those looking for diamonds in the rough should steer clear. The stock currently trades at a 40% premium over our quantitative fair value estimate of $386.43 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's liquidity undermines our estimated valuation. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. For example, the firm's median trading volume over the past 60 days sits in the top 40% globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. We believe this is a sign that shares could be overvalued.

On a different note, the firm's balance sheet is reassuring. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 5.7, a core component of leverage, sits in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.